



**IN THE MATTER OF the Patent Act R.S.C. 1985, c. P-4,  
as amended**

**AND IN THE MATTER OF Alexion Pharmaceuticals Inc.  
and the medicine "Soliris" (the "Respondent")**

**PANEL ORDER WITH REGARDS TO THE BIOTECANADA MOTION FOR LEAVE TO  
INTERVENE**

Decided by the Hearing Panel on the basis of the written record  
Date of Order: May 30, 2016

1. FURTHER to the motion for leave to intervene by BIOTECanada filed on May 18, 2016;
2. AND FURTHER to the consent by the Respondent for leave to intervene for BIOTECanada;
3. AND FURTHER to Board Staff and the British Columbia Ministry of Health not opposing leave to intervene by BIOTECanada on the basis requested by BIOTECanada.

THE PANEL ORDERS THAT:

1. BIOTECanada is granted leave to intervene in this matter solely on the basis sought by BIOTECanada; namely, to file written representations to the Panel regarding the issue of the methodology of the definition of therapeutic classes in Dr. Addanki's report filed by Board Staff.
2. BIOTECanada will file and serve its written submissions in accordance with sections 10 and 11 of the Patented Medicine Prices Review Board Rules of Practice and Procedure by no later than June 15, 2016.

DATED in Ottawa, this 30th day of May, 2016.

Original signed by

Dr. Mitchell Levine on behalf of the Panel.